Teva (TEVA) EVP Evan Lippman awarded 27,347 RSUs vesting through 2030

Rhea-AI Filing Summary

Lippman Evan reported acquisition or exercise transactions in this Form 4 filing.

Teva Pharmaceutical Industries executive Evan Lippman, EVP of Business Development, received a grant of 27,347 restricted share units (RSUs) on March 4, 2026. Each RSU represents a contingent right to receive either one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share.

The RSUs vest in four annual installments: 6,836 on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 6,839 on March 4, 2030. Following this award, Lippman’s reported derivative holdings from this grant total 27,347 RSUs. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, each currently equal to one ordinary share.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lippman Evan

Role EVP, Business Development

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	27,347	$0.00	--

Holdings After Transaction: Restricted Share Units — 27,347 shares (Direct)

Footnotes (1)

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 4, 2026, with 6,836 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 6,839 vesting on March 4, 2030. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippman Evan

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Business Development

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	03/04/2026		A		27,347		(2)	(2)	Ordinary Shares(3)	27,347	$0	27,347	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on March 4, 2026, with 6,836 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 6,839 vesting on March 4, 2030.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Evan Lippman	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TEVA report for Evan Lippman on this Form 4?

Evan Lippman received a grant of 27,347 restricted share units, not an open-market stock purchase or sale. This equity award represents contingent rights to future ordinary shares or their cash value, aligning his compensation with Teva Pharmaceutical Industries’ long-term performance.

How do the 27,347 TEVA restricted share units for Evan Lippman vest over time?

The 27,347 restricted share units vest in four annual tranches. 6,836 RSUs vest on each of March 4, 2027, March 4, 2028, and March 4, 2029, with the remaining 6,839 RSUs vesting on March 4, 2030, creating a long-term vesting schedule.

What does each TEVA restricted share unit granted to Evan Lippman represent?

Each restricted share unit represents a contingent right to receive, upon settlement, one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, linking the award’s value directly to Teva’s share performance.

Are TEVA’s ordinary shares related to American Depositary Shares in this Form 4 filing?

Yes. The filing states that Teva’s ordinary shares may be represented by American Depositary Shares, and each American Depositary Share currently represents one ordinary share. This means the RSUs could effectively translate into an equivalent number of ADSs when settled.

How many TEVA restricted share units does Evan Lippman hold after this reported transaction?

After this grant, Evan Lippman is reported as holding 27,347 restricted share units from this award. The total matches the number of RSUs granted on March 4, 2026, indicating these units reflect his derivative holdings from this specific equity grant.